These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10326738)

  • 1. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
    Mokaddas EM; Sanyal SC
    J Chemother; 1999 Apr; 11(2):93-6. PubMed ID: 10326738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units.
    Bonfiglio G; Laksai Y; Franceschini N; Perilli M; Segatore B; Bianchi C; Stefani S; Amicosante G; Nicoletti G
    Chemotherapy; 1998; 44(5):305-12. PubMed ID: 9732144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
    Mokaddas E; Rotimi VO; Sanyal SC
    J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
    Jones RN; Stilwell MG; Rhomberg PR; Sader HS
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Karlowsky JA; Weaver MK; Thornsberry C; Dowzicky MJ; Jones ME; Sahm DF
    J Clin Microbiol; 2003 Jul; 41(7):3339-43. PubMed ID: 12843088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance patterns of Pseudomonas aeruginosa in tertiary care hospitals of Makkah and Jeddah.
    Khan MA; Faiz A
    Ann Saudi Med; 2016; 36(1):23-8. PubMed ID: 26922684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
    Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
    Harris AD; Perencevich E; Roghmann MC; Morris G; Kaye KS; Johnson JA
    Antimicrob Agents Chemother; 2002 Mar; 46(3):854-8. PubMed ID: 11850272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenemase-producing Pseudomonas aeruginosa in UK.
    Woodford N; Palepou MF; Babini GS; Bates J; Livermore DM
    Lancet; 1998 Aug; 352(9127):546-7. PubMed ID: 9716067
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.